Living Well, Dying Well. a Research Programme to Support Living Until the End (iLIVE)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Terminal Care
- Sponsor
- Erasmus Medical Center
- Enrollment
- 1500
- Locations
- 11
- Primary Endpoint
- Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. The primary outcome for the cohort study is a descriptive assessment of the concerns, expectations and preferences around dying and end-of-life care of patients and their relatives, in different settings and cultures..
Detailed Description
Rationale: In the EU about 4 million people yearly die from a chronic illness. Many of these people die in pain or distress. Care for dying patients and their close relatives is often suboptimal. Objective: To contribute to high-quality personalized care at the end of life by: 1. Providing in-depth understanding of the concerns, expectations and preferences of patients in the last phase of life and their relatives 2. Understanding the cultural, gender, age, healthcare -related and socio-economic variance in these concerns expectations and preferences Study design: The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. Participants are requested to also involve a close relative. Both patients and relatives are asked to fill in a questionnaire, at baseline and after four weeks. If patients die during the study, the relative is asked to fill in a post-bereavement questionnaire. Medical files are studied to assess health care use in the last days of life. Main study endpoints: The primary outcome for the cohort study is a descriptive assessment of patients' concerns, expectations and preferences around dying and end-of-life care, at baseline and after one month of follow-up. Potential risks and benefits associated with participation: The study population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening or stigmatizing participants. If patients feel burdened by participating in the study, they are encouraged to indicate that. The investigators will develop a protocol for researchers and interviewers to address such situations.
Investigators
Agnes van der Heide
Professor
Erasmus Medical Center
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)
Time Frame: One month of follow-up
Self developed questions, which were inspired by the Serious Illness Conversation Guide and the AEOLI questionnaire.
Secondary Outcomes
- European Organisation for Research and Treatment of Cancer Quality of Life C15-Palliative Care questionnaire, quality of life item (range 1-7, with higher score indicating better outcome)(At baseline and after one month of follow-up)
- EuroQol-5d questionnaire (range 1-5 per item, with higher score indicating worse outcome)(At baseline and after one month of follow-up)
- ICECAP Supportive Care Measure (range 1-4 per item, with higher score indicating worse outcome)(At baseline and after one month of follow-up)
- Edmonton Symptom Assessment Scale (range 0-10, with higher score meaning worse outcome)(At baseline and after one month of follow-up)
- Bereaved relatives' experiences(8-10 weeks post-bereavement)
- Use of medical interventions (hospitalisation, medication, surgery, other interventions)(One week)